Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05062785 · ClinicalTrials.gov registry record · Phase 1
Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants
A Phase 1 study, sponsored by Robert Silbergleit.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05062785 is a Phase 1 study that has completed, run by Robert Silbergleit. The registered enrollment target is 24 participants.
The verdict
NCT05062785, a Phase 1 study, has completed, sponsored by Robert Silbergleit.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study is to determine the safety and tolerability of regular insulin (Humulin R) when given intranasally (as drops in nostrils). Healthy participants will be enrolled to determine the maximum tolerated dose of intranasal insulin.
Interventions
- DRUG Intranasal insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2022-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05062785
The ClinicalTrials.gov registry entry for NCT05062785 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robert Silbergleit, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intranasal insulin is the first listed.
NCT05062785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05062785 about?
NCT05062785 is a clinical study titled "Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants". This study is to determine the safety and tolerability of regular insulin (Humulin R) when given intranasally (as drops in nostrils). Healthy participants will be enrolled to determine the maximum tolerated dose of intranasal insulin.
What is the current status of trial NCT05062785?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-10-04. Estimated completion is 2022-04-25.
What interventions are being tested in trial NCT05062785?
The interventions under investigation include: Intranasal insulin (DRUG).
Who is sponsoring clinical trial NCT05062785?
This trial is sponsored by Robert Silbergleit, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.